Geron completes stem cell sale to BioTime subsidiary
This article was originally published in Scrip
It's been almost two years since Geron ended its human embryonic stem cell programs and 11 months since the firm agreed to sell its stem cell assets to BioTime, and the companies finally completed their all-stock transaction on 1 October.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.